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SUUmAry – The aim of this work was to determine serum cut-off levels of hyaluronic acid 
(hA) and laminin (Ln) as predicting factors for liver necro-inflammatory injuries, highlighting 
their diagnostic and therapeutic follow up value in chronic hepatitis b patients. Serum hA and 
Ln were measured in chronic hepatitis b patients (n=35) by eLiSA and compared with control 
group (n=20). Liver histopathologic parameters were evaluated according to the modified Knode-
ll score. The mean serum hA and Ln concentrations in patients (108.4±58.7 and 95.0±20.1 ng/
mL, respectively) were greater than those in controls (46.6±10.6 and 46.1±10.2ng/mL, respectively; 
p<0.001). Serum levels of hA and Ln in all stages and grades of hepatic fibrosis and inflammation 
were significantly higher than those in the control group of healthy subjects (p<0.05). Cut-off levels 
of 52.0 ng/mL hA and 64.0 ng/mL Ln in serum for discrimination of patients with liver fibrosis 
from those without liver fibrosis showed acceptable AUC, sensitivity and specificity. After 6 months 
of treatment, a decrease was observed in serum hA and Ln levels; however, the levels were still 
higher than those in the control group (p<0.05). The correlation of fibrosis stages (not inflammation 
grades) with serum hA and Ln levels was significant (p<0.01). The findings suggested the increase 
in serum hA and Ln concentrations above the predictive values (52.0 ng/mL hA and 64.0 ng/mL 
Ln, respectively) to be associated with liver fibrosis. Therefore, serum hA and Ln levels could be 
determined as an additional clinical tool for evaluation of liver fibrosis, when liver biopsy is impo-
ssible to perform.
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Introduction
Staging of liver fibrosis and evaluation of inflam-
mation grade is useful for (a) estimating the rate of 
liver fibrosis progression; (b) choice of treatment; and 
(c) monitoring disease recovery. Liver biopsy is still 
the reference test for staging and grading of hepatic 
fibrosis and inflammation. Therefore, due to some 
limitations of liver biopsy, noninvasive methods are 
preferred1.
Liver fibrosis is a process involving production and 
deposition of various components that constitute the 
extracellular matrix. Some of these components are 
noncollagenous glycoproteins such as laminin, col-
lagens, hyaluronic acid, and proteoglycans. in recent 
years, some studies have proposed hyaluronic acid 
(hA) and laminin (Ln) as indices of the extent of 
liver fibrosis in chronic liver diseases1,2.
hyaluronic acid is a linear polymer distributed in 
the extracellular spaces and built from D-glucuronic 
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acid and n-acetyl-D-glucosamine. in the liver, hA 
is produced by the hepatic stellate cells and degraded 
by the sinusoidal endothelial cells. An increase in hA 
levels was observed in chronic hepatitis C and cirrho-
sis patients2.
One of the main glycoproteins of the basement 
membrane is Ln, which is produced by hepatocytes 
and sinusoidal cells of the liver3. An increase in serum 
Ln levels was observed in advanced stages of fibrosis 
(in patients with hepatic disease)4-7. Kropf et al. report 
that determination of Ln and hA serum concentra-
tions are sensitive tests for diagnosis of hepatic fibrotic 
disease and portal hypertension8,9.
in the iranian population, there are few published 
studies10,11 concerning the relationship of hA and Ln 
serum levels with liver fibrosis stage or inflammation 
grade in chronic hepatitis b patients. The published 
studies used the ishak scoring system to assess liver 
fibrosis in liver biopsy, and there is no report on the 
relationship of hA and Ln serum levels with liver 
necro-inflammatory injuries according to the modi-
fied Knodell score system. Therefore, the main aims of 
this study were: (a) determination of serum hA and 
Ln cut-off levels as predictive factors for liver fibrosis 
and inflammation; (b) applicability of these tests in 
staging of necro-inflammatory injuries as compared 
with the results obtained by histologic tests (modified 
Knodell score system); and (c) treatment follow up by 




Among subjects referred to the Liver and Gastro-
intestinal Diseases research Centre of  tabriz and 
Gonbad (north of iran), 35 patients (20 men and 15 
women, aged 35.6±11.8 years) were selected. Patients 
were included in the study if they were positive for 
serum hepatitis b surface antigen (hbsAg) and had 
persistently elevated serum aminotransferases greater 
than 1.5 upper limit of the reference range for at least 
six months. Patients with a history of gastrointesti-
nal bleeding and other chronic liver diseases (chronic 
hepatitis C, autoimmune hepatitis, Wilson’s disease, 
hemochromatosis, alpha1-antitrypsin deficiency, bil-
iary disease, hepatocellular carcinoma), active intra-
venous drug abuse, and liver transplantation were ex-
cluded. Only patients that had fibrosis stage ≥1 were 
treated and followed up for at least six months. Patients 
were treated according to the standard protocol with 
interferon (3 million units 3 times per week) or ad-
efovir (10 mg/day) or lamivudine (100 mg/day)12. All 
study patients underwent liver biopsy for assessment 
of liver fibrosis score and were subclassified according 
to the histological activity index (hAi) score.  
Control sera for determination of hA and Ln was 
obtained from 20 healthy volunteers referred to the 
tabriz University of medical Sciences (10 women and 
10 men, mean age ± SD 42±14.7 years). These healthy 
persons had normal serum levels of aminotransferases 
and alkaline phospahtase (ALP), were negative for 
hbsAg, and therefore did not require liver biopsy. 
These subjects had no history of gastrointestinal bleed-
ing and chronic liver disease, smoking (never smoker), 
alcohol intake (never drinker), no family history of 
hepatitis and liver disease, and no active intravenous 
drug abuse and liver transplantation, according to the 
information gathered in the questionnaire form. The 
subjects that smoked (>1 cigarette/day) and took alco-
hol drinks (>5 g/day) were classified as smokers and 
alcohol drinkers.
All subjects gave their written informed consent 
to use these data for scientific purposes and the tabriz 
University of medical Sciences ethics Committee ap-
proved the study.
Blood sampling and analysis
blood samples (5 mL) were collected after an over-
night fast on the day before treatment initiation. in 
addition, fasting venous blood (5 mL) was also sam-
pled at two-month intervals, i.e. at two, four and six 
months of treatment initiation. Serum was separated 
at 2500 g for 5 minutes. hepatitis b serology and liver 
function tests (Lft), including ALP, alanine ami-
notransferase (ALt) and aspartate aminotransferase 
(ASt) were performed on aliquots of each sample us-
ing commercially available kits. in brief,  ALP was 
assayed with PnPP (para nitrophenyl phosphate) as 
a substrate (Ziestchem kit, tehran, iran) and serum 
aminotransferases (ASt and ALt) were measured 
according to reitman and frankel by colorimetric test 
(Ziestchem kit, tehran, iran) with 2, 4 DnPh (2, 4 
dinitrophenylhydrazone) on an Apel spectrophotom-
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eter (PD303S, Japan). The hepatitis b serology mark-
ers were analyzed on an eLiSA reader (norahan fajr, 
iran) using the following kits: hepatitis b surface an-
tigen (hbsAg; Diakey, Shinjin medics inc. eLiSA 
kit, Korea), hepatitis b surface antibody (hbsAb; 
Diakey, Shinjin medics inc. eLiSA kit, Korea) and 
hepatitis b core antibody (hbcAb; Dia-Pro eLiSA 
kit, italy). 
The rest of blood samples were stored at -20 ºC. 
Serum hA and Ln levels were determined in all sera 
upon completion of blood sampling. 
Serum hA and Ln were assayed using an eLi-
SA reader (immunoscan, Lab System, Switzerland) 
and the following kits, respectively: hA-eLiSA Kit 
(hA-test, product number: K-1200, echelon biosci-
ence inc., USA) and Ln eiA Kit (takara bio, code 
number: mK107). 
Serum HA assay
Serum hA levels were determined by an hA-
eLiSA kit. The hA-eLiSA method is a competitive 
eLiSA in which the colorimetric signal is inversely 
proportional to the amount of hA present in the 
sample. The concentration of hA in the samples was 
determined from a standard curve using the reagent 
blank (0 ng hA/mL) and hA reference solutions (50, 
100, 200, 400, 800 and 1600 ng hA/mL). Serum hA 
concentrations were determined in one analytical batch 
on one working day. The intra-assay variability (coef-
ficient of variation, Cv) of the procedure according to 
the manufacturer’s declaration was 5%.
Serum LN assay
Serum Ln concentrations were assayed using an 
Ln eiA Kit. The Ln eiA kit is a solid phase eiA 
based on a sandwich method that utilizes two mouse 
monoclonal anti-Ln antibodies to detect Ln by a 
two-step procedure. The amount of Ln was deter-
mined by measuring the absorbance using an eiA 
plate reader. A standard curve of 5, 10, 20, 40, 80, 160 
and 320 ng/mL Ln was used to convert sample absor-
bance into ng Ln/mL serum. The intra-assay and in-
ter-assay variability (Cv) of the procedure according 
to the manufacturer’s declaration was 4.0%-5.7% and 
0.3%-5.0%, respectively. Again serum Ln concentra-
tions were determined in one analytical batch on one 
working day. Control samples were analyzed in the 
same manner, except that the control group provided 
blood only once at entry. 
Histologic assessment of liver damage
All study patients underwent percutaneous liver 
biopsy (with a trucut needle number 16 guided by b 
type ultrasound) to confirm the presence of liver fi-
brosis and to assess the severity of liver disease. biopsy 
fragments were fixed in 10% formalin solution for 12 
hours and fixed in paraffin. Sections were stained 
with hematoxylin-eosin, masson’s trichrome and re-
ticulin stain to establish the histologic diagnosis and 
the extent of liver lesions. Specimens were graded and 
staged according to the modified Knodell scoring sys-
tem13. 
The fibrosis scores were determined on the basis of 
the following instructions: stage 0, no fibrosis; stage 1, 
fibrous expansion of some portal areas, with or with-
out short fibrous septa; stage 2, fibrous expansion of 
most portal areas, with or without short fibrous septa; 
stage 3, fibrous expansion of most portal areas with 
occasional portal to portal (P-P) bridging; stage 4, fi-
brous expansion of portal areas with marked bridging 
[portal to portal (P-P) as well as portal to central (P-
C)]; stage 5, marked bridging (P-P and/or P-C) with 
occasional nodules (incomplete cirrhosis); and stage 6, 
probable or definitive cirrhosis. 
The grading system scored 0-18 and was based on 
sum of four indices: piecemeal necrosis (score 0-4), 
confluent necrosis (score 0-6), focal lytic necrosis 
(score 0-4), and portal inflammation (score 0-4)13.
Statistical analysis
All statistical analyses were done by SPSS version 
12.0 for microsoft Windows (SPSS inc.) and a p value 
less than 0.05 was considered statistically significant. 
numerical data were expressed as mean ± SD. mean 
of serum hA and Ln levels of the patient group as a 
whole and various chronic hepatitis stages and con-
trol group were compared using nonparametric test 
(mann-Whitney U test) and AnOvA model. Spear-
man’s correlation coefficients (rS) were calculated to 
assess the relationship between the histologic degree 
of liver fibrosis stages (or inflammation grades) with 
the concentrations of serum hA and Ln and Lft. 
to assess and compare diagnostic accuracy of serum 
hA and Ln levels for discrimination of patients with 
h. Parsian et al. Serum hyaluronic acid and laminin concentrations in hepatitis b patients
260 Acta Clin Croat,  Vol. 49,  No. 3,  2010
liver fibrosis from healthy individuals, we plotted the 
receiver operating characteristic curves (rOC) and 
calculated the areas under the curves (AUC) for com-
parison14. The rOCs were generated by plotting the 
relationship of true positivity (sensitivity) and false 
positivity (1- specificity) at various cut-off points of 
the test. An AUC of 1.0 is characteristic of an ide-
al test, whereas 0.5 indicates a test of no diagnostic 
value15. The diagnostic sensitivity, specificity, positive 
predictive value (PPv) and negative predictive value 
(nPv) were also calculated.
Results
histologic examination of the liver for fibrosis 
scoring revealed fibrosis stage 0 in eight patients; 
these patients were excluded and the rest were treated 
and followed up. The results of laboratory tests, pre-
sented in table 1, showed that serum ALt, ASt and 
ALP levels in patient group were significantly higher 
than those in control group (p<0.05), and revealed 
the presence of hepatocellular disorders in the for-
mer. table 1 also shows the mean serum hA and Ln 
concentrations (±SD) in patients and healthy control 
Table1. Comparison of serum aspartate aminotransferase 
(AST), alanine aminotransferase (ALT) and alkaline 
phosphatase (ALp) activities, hyaluronic acid (HA) and 
laminin (LN) levels (mean ± SD) in patient and control 
groups (Mann-Whitney U test)
variable Patient group Control group
ALt (iU/L) 110.4±72.7‡ 27.3±6.4
ASt (iU/L) 62.0±34.5† 28.3±6.5
ALP (iU/L) 228.4±156.6† 130.6±38.1
hA (ng/mL) 108.4±58.7‡ 46.6±10.6
Ln (ng/mL) 95.0±20.1‡ 46.1±10.2
Table 2. Comparison of serum hyaluronic acid (HA) and laminin (LN) concentrations between patient subgroups (stages of 













































































hA 251.0 230.0 220.0 210.0
Ln 149.0 141.0 122.0 115.0
*6
(n=1)
hA 285.0 249.0 232.0 215.0
Ln 143.0 138.0 127.0 115.0
*in fibrosis stages 5 and 6, presented by only one patient each, comparison was not performed; **two, four and six months of treatment initiation.
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subjects. The results showed serum hA and Ln levels 
to be statistically significantly increased in patients as 
compared with healthy controls (p<0.001).
tables 2 and 3 show comparison of serum hA and 
Ln concentrations between patient subgroups (stages 
of fibrosis and grades of inflammation) and control 
group at entry and during the treatment period. As 
shown in these tables, serum levels of hA and Ln 
were significantly higher in all stages of hepatic fi-
brosis and grades of inflammation as compared with 
control group (p<0.05). The fibrosis stages 5 and 6, 
and inflammation grades 3, 5, 6 and 10-12 were pres-
ent in only one patient each, and therefore could not 
be compared with the control group, thus only serum 
levels of hA and Ln are presented. Also, there were 
no patients with inflammation grades 13-18. After the 
beginning of treatment, a gradual decrease in serum 
hA and Ln levels was observed and was statistically 
significant. As shown in figures 1 and 2, Spearman 
correlation coefficient (rS) for hA and Ln was rS=-
0.193 (p=0.045) and rS=-0.326 (p=0.001), respective-
ly. however, after six-month treatment, serum levels 
of hA and Ln in these patients versus healthy control 
group were still high and the difference was statisti-
cally significant (p<0.05). 
table 4 shows correlation analysis of the serum 
biochemical profile and histopathologic parameters 
of patients with chronic hepatitis b disease. Correla-
tions between these parameters were calculated by the 
Spearman correlation coefficient.
table 5 presents rOC data of hA and Ln serum 
levels for discrimination of patients with liver fibrosis 
and control group. A cut-off level of 52.0 ng hA/mL 
and 64.0 ng Ln/mL for discrimination of patients 
with liver fibrosis from those without liver fibrosis 
showed good sensitivity, specificity, PPv and nPv. 
Discussion
The mean serum hA and Ln levels in patients 
were significantly higher than those in healthy controls 
(p<0.001), as shown in table 1. Our data are consis-
tent with the work of other groups that have reported 
increased levels of serum hA and Ln in chronic liver 
disease, particularly in patients with cirrhosis4-11,16.
Patients in higher stages of liver fibrosis and grades 
of inflammation had higher serum hA and Ln con-
centrations (tables 2 and 3). According to these tables, 
differences in serum levels of hA and Ln in vari-
ous sampling stages during the treatment protocol as 
Fig. 2. Correlation analysis between mean serum laminin 
(LN) concentrations at entry and and two (2nd), four (3rd) 
and six (4th sampling) months of treatment initiation (rS=-
0.326; P=0.001).
Fig. 1. Correlation analysis between mean serum hyaluronic 
acid (HA) concentrations at entry and two (2nd), four (3rd) 
and six (4th sampling) months of treatment initiation (rS=-
0.193; P=0.045).
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compared with healthy controls were statistically sig-
nificant (p<0.05). in early stages of liver fibrosis (stag-
es 0-2) and inflammation grades (grades 0-5), serum 
hA and Ln concentrations were high and the high-
est levels were observed in liver fibrosis stages ≥3 and 
inflammation grade ≥6. it seems that the progression 
of liver fibrosis and inflammation was accompanied by 
impairment in the liver endothelial cell function and 
reduced degradation of these components, eventually 
Table 3. Comparison of serum hyaluronic acid (HA) and laminin (LN) concentrations (mean ± SD) between patient 













































hA 81.0 76.0 70.0 65.0



















hA 90.0 94.0 82.0 86.0
Ln 89.0 84.0 78.0 76.0
*6
(n=1)
hA 134.0 123.0 121 119.0



















hA 251.0 230.0 220.0 210.0
Ln 149.0 141.0 122.0 115.0
*11
(n=1)
hA 205.0 175.0 178.0 182.0
Ln 114.0 91.0 89.0 85.5
*12
(n=1) 
hA 178.0 161.0 169.0 115.0
Ln 118.0 115.0 106.0 115.0
*in inflammation grades 3, 5, 6 and 10-12, presented by only one patient each, comparison was not performed; also, we had no patients with 
inflammation grades 7, 9 and 13-18; **two, four and six months of treatment initiation.
resulting in elevation of serum hA and Ln concen-
trations. Castera et al.7 report that Ln concentration 
increases in early stages of chronic liver disease and 
the highest concentrations were recorded in active cir-
rhosis and chronic active hepatitis. in other reports, it 
is proposed that determination of serum levels of Ln 
and hA can be used for the diagnosis of hepatic fi-
brotic disease and portal hypertension8,9. Korner et al. 
report that among various serum parameters such as 
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Ln, A1-apolipoprotein, prothrombin time and hA, 
serum hA level was most strongly correlated with the 
stage of liver fibrosis, and can be used for long-term 
monitoring of disease progression17. 
After the beginning of treatment, a gradual de-
crease in serum hA and Ln level were observed, but 
after six months of treatment, serum levels of hA and 
Ln in these patients was still higher as compared with 
control group, were the differences being statistically 
significant. in a study by Guechot et al.18, hA serum 
concentrations were significantly lower after treatment 
in chronic hepatitis patients. in another study, hA lev-
els were demonstrated to decrease during treatment in 
parallel to improvement in fibrosis staging; clinical use-
fulness of hA was its ability to exclude patients with 
significant fibrosis and cirrhosis19. 
in our study, there was a significant relationship 
between serum levels of hA and Ln and liver fibro-
sis stages (p<0.01) both at entry and during the treat-
ment, but the correlation with inflammation grades 
revealed a different pattern. At entry, the correlation 
was statistically significant (p<0.01), but during the 
treatment the correlation was not statistically signifi-
cant. maybe the treatment protocol led to a decrease 
in inflammation factors and caused regeneration of 
liver endothelial cells. Thus regenerated endothelial 
cells better metabolized hA and Ln, and a decrease 
in serum levels of hA and Ln occurred and caused an 
indefinite correlation. 
As shown in table 4, the correlations between 
stages of fibrosis and inflammation grades with se-
rum aminotransferases and ALP were not statistically 
significant, but the grades of inflammation showed 
better correlation with aminotransferases. interest-
ingly, we also found that serum hA levels had good 
correlation with serum Ln levels at entry and during 
the treatment protocol (p<0.01). This suggested that 
during the liver fibrinogenesis, extracellular matrix 
components such as hA and Ln increased simulta-
neously.
Table 4. Correlation analysis of serum and 
histopathologic parameters in chronic hepa-
titis B patients (correlations between these 
parameters were calculated by Spearman 
correlation coefficient)
Liver biopsy evaluation: stage = stage of fibrosis; grade = grade of inflammation; laboratory parameters: 
hA1 and Ln1 = serum hA and Ln levels at entry; hA2-4 and Ln2-4: serum hA and Ln levels at 
two, four and six months of treatment initiation; ASt = aspartate aminotransferase; ALt = alanine 
aminotransferase;  ALP = alkaline phosphatase; statistics: rS = Spearman correlation coefficient; p = p 
value; †p<0.05; ‡p<0.01.
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Table 5. ROC curve of serum hyaluronic acid (HA) and laminin (LN) levels for discrimination of patients with liver fibrosis 
and control group (HA cut-off level = 52.0 ng/mL and LN cut-off level = 64.0 ng/mL)





hA 0.962(0.861-0.992) 0.000 91.4 80 88.8 84.2
Ln 0.986(0.962-1.009) 0.000 94.3 90 94.3 90
AUC = area under the curve; Ci = confidence interval; PPv = positive predictive value; nPv = negative predictive value.
The cut-off levels of 52.0 ng hA/mL and 64.0 ng 
Ln/mL for discrimination of patients with liver fi-
brosis from those without liver fibrosis showed good 
sensitivity, specificity, PPv and nPv. The AUCs of 
serum hA and Ln in rOC analysis were 0.962 and 
0.986, respectively. it means that serum hA and Ln 
can discriminate patients with liver fibrosis and healthy 
individuals. Comparable results were obtained for the 
diagnosis of liver fibrosis at the same cut-off values in 
other studies20,21.
Several mechanisms have been proposed for the 
elevation of serum hA and Ln levels in chronic hep-
atitis patients. increased production of these compo-
nents in the liver and the lack of degradation by liver 
endothelial cells are the major causes of elevation of 
serum hA and Ln levels in chronic hepatitis patients 
as compared with healthy individuals1. 
in conclusion, the findings of this study suggest 
that measurement of serum hA and Ln concentra-
tions can discriminate between patients with liver 
fibrosis (but not inflammation grades) and healthy 
individuals and can give information about progres-
sive changes in the liver with reduced function of liver 
endothelial cells. it seems that serum hA and Ln 
concentrations are associated with histopathologic 
changes in chronic liver disease according to the mod-
ified Knodell scoring system and an increase in serum 
concentrations of hA and Ln above the predictive 
value (hA cut-off level = 52.0 ng/mL and Ln cut-off 
level = 64.0 ng/mL) is related to liver fibrosis. There-
fore, we can determine serum hA and Ln levels as an 
additional clinical tool for evaluation of liver fibrosis. 
in addition, it seems that measurement of serum hA 
and Ln levels can be useful for long-term monitoring 
of disease progression during the treatment protocol, 
where liver biopsy cannot be performed.
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Sažetak
PrOCJenA rAZvOJA Jetrene fibrOZe U bOLeSniKA S KrOniČnim hePAtitiSOm b
ODreĐivAnJem hiJALUrOnSKe KiSeLine i LAmininA
H. parsian, A. Rahimipour, M. Nouri, M. Hossein Somi i D. Qujeq
Cilj ove studije bio je utvrditi prijelomne vrijednosti hijaluronske kiseline (hA) i laminina (Ln) u serumu kao čim-
benike koji predskazuju nekrotično-upalna oštećenja jetre, te ukazati na njihovu vrijednost u dijagnosticiranju i praćenju 
terapijskog učinka u liječenju bolesnika s kroničnim hepatitisom b. razine hA i Ln u serumu mjerile su se kod bolesnika 
s kroničnim hepatitisom b (n=35) pomoću metode eLiSA i usporedile s razinama u kontrolnoj skupini (n=20). Jetreni 
histopatološki parametri procjenjivali su se prema modificiranom Knodellovom bodovnom sustavu. Srednje serumske 
koncentracije hA i Ln bile su više kod bolesnika (108,4±58,7 odnosno 95,0±20,1 ng/mL) nego u kontrolnoj skupini 
(46,6±10,6 odnosno 46,1±10,2 ng/mL; p<0,001). U usporedbi s kontrolnom skupinom zdravih ispitanika serumske razine 
hA i Ln bile su značajno više u svim stadijima jetrene fibroze i stupnjevima upale u skupini bolesnika (p<0,05). Prijelo-
mne vrijednosti od 52,0 ng/mL hA i 64,0 ng/mL Ln u serumu za razlikovanje bolesnika s jetrenom fibrozom od onih bez 
nje pokazale su prihvatljivu vrijednost AUC, osjetljivost i specifičnost. nakon 6 mjeseci liječenja zabilježeno je sniženje 
serumskih razina hA i Ln, ali su te razine još uvijek bile više od onih u kontrolnoj skupini (p<0,05). Korelacija stadija 
fibroze (ne i stupnjeva upale) sa serumskim razinama hA i Ln bila je značajna (p<0,01). Ovi nalazi ukazuju na to da je 
porast serumskih koncentracija hA i Ln iznad prediktivnih vrijednosti (52,0 ng/mL hA i 64,0 ng/mL Ln) udružen s 
jetrenom fibrozom. Stoga bi se serumske razine hA i Ln mogle određivati kao dodatno kliničko sredstvo u procjenjivanju 
jetrene fibroze kad nije moguća biopsija jetre.
Ključne riječi: Hepatitis B, kronični – krv; Biološki biljezi – krv; Hijaluronska kiselina – krv; Jetrena ciroza

